Operator
Hello, and welcome to the Chrysos Corporation Full Year 2026 Results Conference Call. [Operator Instructions] I would now like to turn the conference over to Dirk Treasure, Managing Director and CEO. You may begin.
Dirk Treasure
MD, CEO & Executive Director
Thank you very much, and good morning, shareholders. Thank you all for joining us today for our FY ’26 results presentation. As usual, I’m joined by our CFO, Brett Coventry, as well as by our CPO, Kim Boland. FY ’26 was another strong year for Chrysos. We delivered at the upper end of our guidance, processed record sample volumes, expanded our contracted fleet and strengthened the operating platform that supports our next stage of growth. I’ll begin with the highlights and the progress we’ve made in expanding PhotonAssay globally. Brett will then take you through the financial results before I return to cover our growth opportunity and the outlook for FY ’27.
Slide 4, please, operator. FY ’26 has been another year of strong adoption of our PhotonAssay technology, and we continue to demonstrate our ability to grow revenue faster than cost at scale. Revenue increased 33% to $88.1 million, and EBITDA increased 68% to $27.2 million, with the EBITDA margin expanding from 24% in FY ’25 to 31% this year. We continue to generate cash flow with $17.9 million net inflow for the year, supporting our ongoing growth.
